Filing Flows › TScan Therapeutics (TCRX) › Q2 2026 › vs Q1 2026
TScan Therapeutics (TCRX) Q2 2026 vs Q1 2026 (quarter over quarter)
TScan Therapeutics's revenue rose $69K (+7%) from $982K in Q1 2026 to $1.1M in Q2 2026.
TScan Therapeutics, Q2 2026: revenue $1.1M (-66% year over year), net loss $30.4M, operating cash flow −$27.5M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.1M | $982K | $69K | +7% |
| Other income, net | $134K | $473K | −$339K | -72% |
| Net loss | $30.4M | $28.7M | $1.7M | +6% |
| Costs & expenses | $31.5M | $30.1M | $1.4M | +5% |
| Operating costs | $31.5M | $30.1M | $1.4M | +5% |
| Research & development | $23.4M | $21.9M | $1.5M | +7% |
| General & admin | $8.1M | $8.2M | −$75K | -0.9% |
| Operating cash sources | $30.6M | $27.4M | $3.2M | +11% |
| Depreciation | $699K | $693K | $6K | +0.9% |
| Share-based compensation | $2.4M | $2.5M | −$108K | -4% |
| Cash used in operations | $27.5M | $24.3M | $3.3M | +13% |
| Net loss absorbed | $30.4M | $28.7M | $1.7M | +6% |
| Working capital & other | $232K | −$1.2M | $1.5M | — |
Questions
How much did TScan Therapeutics's revenue grow quarter over quarter in Q2 2026?
TScan Therapeutics's revenue rose $69K (+7%) from $982K in Q1 2026 to $1.1M in Q2 2026.